Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantourage Group SEFRA:HIGH +2.91%20 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2025, which is at its 10-year median of 23.10. GuruFocus rates FRA:HIGH with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 809 Drug Manufacturers companies, Cantourage Group SE ranks better than 72.56% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cantourage Group SE was 23.10% per year. The lowest was 23.10% per year. And the median was 23.10% per year.
Cantourage Group SE (FRA:HIGH) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cantourage Group SE 3-Year EBITDA Growth Rate Related Terms
FRA:HIGH vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's 3-Year EBITDA Growth Rate falls into.
Cantourage Group SE 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.10% mean?
Cantourage Group SE (FRA:HIGH) has a 3-Year EBITDA Growth Rate of 23.10% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cantourage Group SE and its competitors. This is near median its historical median of 23.10. Over the past decade, Cantourage Group SE's 3-Year EBITDA Growth Rate has ranged from 23.10 to 23.10. According to the industry distribution chart, Cantourage Group SE ranks #222 out of 809 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Cantourage Group SE's 3-Year EBITDA Growth Rate too high?
Cantourage Group SE's current 3-Year EBITDA Growth Rate of 23.10% is near median its 10-year median of 23.10. Over the past 10 years, this metric has ranged from a low of 23.10 to a high of 23.10. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Cantourage Group SE's value of 23.10% is 159.6% above this industry median. Based on the distribution chart, Cantourage Group SE ranks #222 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cantourage Group SE has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #222 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Cantourage Group SE in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Cantourage Group SE's value of 23.10% is 159.6% above this benchmark. Historically, Cantourage Group SE's own 3-Year EBITDA Growth Rate has ranged from 23.10 to 23.10 over the past decade. While the company's 10-year median is 23.10 vs. the industry median of 8.90, Cantourage Group SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current 3-Year EBITDA Growth Rate of 23.10% is 159.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current 3-Year EBITDA Growth Rate is 23.10%, which is near median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (FRA:HIGH) has a current 3-Year EBITDA Growth Rate of 23.10%. The current 3-Year EBITDA Growth Rate is 23.10%, which is near median its 10-year median of 23.10 and 159.6% above the Drug Manufacturers industry median of 8.90. Cantourage Group SE's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cantourage Group SE (FRA:HIGH), the current 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
20GF Score
Get the complete analysis for FRA:HIGH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HIGH has been successfully added to your 
